Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study.

Abstract

Osteogenesis imperfecta (OI) is an hereditary disease characterized by low bone mass, increased bone fragility, short stature, and skeletal deformities, few treatment options are currently available. Neridronate is an amino-bisphosphonate, licensed in Italy for the treatment of OI and Paget's disease of bone. A characteristic property of neridronate is that it can be administered both intravenously and intramuscularly, providing an useful system for administration in homecare. Neridronate appears to increase Bone Mineral Density (BMD) in adults with OI and reduces bone resorption by inhibition of osteoclastic activity. Teriparatide (recombinant 1-34 N terminal sequence of human parathyroid hormone) is the first anabolic agent approved for the treatment of patients with osteoporosis and has been reported to increase bone formation by stimulating osteoblast differentiation, osteoblast function, and survival. The results of this study showed a promising role of teriparatide in the therapy of OI type I.

• Authors: Paolo Tranquilli Leali, Massimo Balsano, Gianluca Maestretti, Matteo Brusoni, Veronica Amorese, Emanuele Ciurlia, Matteo Andreozzi, Gianfilippo Caggiari, Carlo Doria
• Journal: Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases (Clin Cases Miner Bone Metab) 2017 May-Aug Vol. 14 Issue 2 Pg. 153-156 ISSN: 1724-8914 [Print] Italy
• PMID: 29263724 (Publication Type: Journal Article)